MTI Issue 59

Page 1

www.med-technews.com Issue 59 | May/June 2022

@medtechonline

MED-TECH INNOVATION | NEWS MED-TECH

PLUS innovation New Medilink Midlands CEO outlines his vision Regulatory issues surrounding AI Automating data collection to streamline compliance

Going beyond borderS - AN ITALIAN FEEL TO MED-TECH INNOVATION EXPO

MEDICAL DEVICE SUPPLY CHAIN INTELLIGENCE


LA LA B BO OR R AT AT O OR RY Y S SE ER RV V II C CE ES S

Need Need Accredited Accredited Package Package Testing? Testing? ® Let Laboratory Services Services Help! Help! Let Nelipak Nelipak® Laboratory Our Our independent, independent, full-service full-service package package testing testing laboratory laboratory is INAB Accredited to ISO 17025 and can make is INAB Accredited to ISO 17025 and can make sure sure your your products products meet meet FDA FDA & & CE CE mark mark requirements; requirements; comply comply with with ISO ISO 11607-1; 11607-1; maintain maintain sterile sterile barrier barrier integrity and more to support new product integrity and more to support new product development development or or revisions revisions with with patient patient safety safety ultimately in mind. ultimately in mind. We We offer offer aa comprehensive comprehensive range range of of tests tests including: including: »» Accredited Accredited test test methods methods »» Transportation testing Transportation testing »» Accelerated Accelerated and and real-time real-time aging aging »» Package and seal integrity Package and seal integrity »» Mechanical Mechanical testing testing of of materials materials »» Analytical testing Analytical testing »» Independent, Independent, high-quality high-quality testing testing reports reports Why Why choose choose Nelipak Nelipak for for your your testing testing needs? needs? We are committed to achieving and maintaining We are committed to achieving and maintaining aa high high standard standard of of quality quality and and service service in in all all aspects aspects of of our laboratory testing. This commitment is our laboratory testing. This commitment is underpinned underpinned by by our our team team who who provide provide aa highly highly professional professional and and confidential service in our secure facility confidential service in our secure facility offering offering our our customers customers the the following following benefits; benefits; »» »» »» »» »» »»

Free Free up up internal internal resources resources Access to an expert Access to an expert team team and and advice advice Comprehensive Comprehensive reports reports Fast Fast completion completion of of your your key key projects projects Complaint Complaint Investigation Investigation Material comparison Material comparison

www.nelipak.com www.nelipak.com

®

Nelipak® Nelipak Elsham, United Elsham, United Kingdom Kingdom

®

Nelipak® Nelipak Galway, Ireland Galway, Ireland

®

Nelipak® Nelipak Heredia, Costa Rica Heredia, Costa Rica

Nelipak® Corporate Nelipak Corporate Office Office Cranston, RI, USA Cranston, RI, USA Nelipak® Nelipak Clara, Ireland Clara, Ireland Nelipak® Nelipak Derry, Northern Ireland, Derry, Northern Ireland, UK UK

®

®

®

®

Nelipak® Nelipak Humacao, Puerto Rico Humacao, Puerto Rico ®

Nelipak® Nelipak Phoenix, AZ, USA Phoenix, AZ, USA ®

Nelipak® Nelipak Venray, The NetherVenray, The Netherlands lands

®

Nelipak® Nelipak Whitehall, PA, USA Whitehall, PA, USA


CONTENTS regulars

5.

Comment

Ian Bolland explains why he’s excited about this year’s MedTech Innovation Expo

6.

Making Medtech

A round-up of the latest industry news

12.

Cover Story

Ian Bolland speaks to Filippo Mansani from the Italian Trade Agency about the strong presence from the country at this year’s Med-Tech Innovation Expo

16.

Med-Tech Innovation Expo

In addition to his editor’s letter, Ian Bolland provides his preview to this year’s MedTech Innovation Expo

27.

Digital Health

Miiskin’s founder outlines the technological advances seen in dermatology

34.

Real World Medtech

Nuance Hearing explains its solution for the 'cocktail party problem'

THE TEAM editor | ian bolland ian.bolland@rapidnews.com portfolio sales manager | christine joinson +44 (0)1244 952 385 christine.joinson@rapidnews.com portfolio sales manager | victoria dunsmore +44 (0)1244 952 247 victoria.dunsmore@rapidnews.com portfolio sales manager | caroline jackson +44 (0)1244 952 358 caroline.jackson@rapidnews.com

features

10.

Medilink

MED-TECH

Med-Tech Innovation speaks to the new chief executive of Medilink Midlands Simon Himsworth about his vision for the company and his outlook on the industry

INNOVATION | NEWS

15.

Sustainability

Wideblue considers many of the practices under the microscope as companies strive for their sustainability goals

12

21.

Microfluidics

Xi Engineering outlines the importance of microfluidics in medical technology ahead of its MedTech Innovation Expo return

10

23.

Testing & Inspection

Velentium discuss test systems and why they should be developed in parallel with medical devices

15

29.

Regulation

Medidata examines the regulatory issues when it comes to the increasing use of AI in medtech

vp sales & sales talent | julie balmforth julie.balmforth@rapidnews.com head of studio & production | sam hamlyn designer | robert wood publisher | duncan wood

Rapid Medtech Communications Ltd. Carlton House, Sandpiper Way, Chester Business Park, Chester, CH4 9QE MTI PRINT SUBSCRIPTION – QUALIFYING CRITERIA UK & Ireland – Free Europe – £249 ROW – £249

FREE on iOS and Android devices Subscription enquiries to subscriptions@rapidnews.com

27

The Publisher endeavours to collect and include complete and current information in Med-Tech Innovation, but does not warrant that any or all such information is complete, correct or current. The Publisher does not assume and hereby disclaims any liability to any person or entity for any loss or damage caused by errors or omissions of any kind, whether resulting from negligence accident or any other cause.

Med-Tech Innovation does not verify any claims or other information appearing in the advertisements contained in the publication and cannot take any responsibility for any losses or other damages incurred by readers in reliance on such content. All submissions are handled with care. Every precaution is taken to ensure accuracy, but the Publisher cannot accept responsibility for the accuracy of the information here. ©Rapid Medtech Communications Ltd. No part may be reproduced or transmitted in any form without the prior permission of the Publisher. ISSN 2046-5424

3


䴀䔀䐀䤀䌀䄀䰀䰀夀 䄀倀倀刀伀嘀䔀䐀 ⴀ 倀伀圀䔀刀 匀伀䰀唀吀䤀伀一匀 ⴀ

䈀䄀吀吀䔀刀夀 倀䄀䌀䬀匀

䐀䔀匀䬀吀伀倀 䈀䄀吀吀䔀刀夀 䌀䠀䄀刀䜀䔀刀匀

伀倀䔀一 䘀刀䄀䴀䔀

唀匀䈀 倀伀圀䔀刀 匀唀倀倀䰀䤀䔀匀

䘀䔀䄀吀唀刀䔀䐀 一䔀伀 䴀䔀䐀䤀䌀䄀䰀 倀伀圀䔀刀 匀唀倀倀䰀䤀䔀匀

䠀愀爀攀搀愀琀愀 䔀氀攀挀琀爀漀渀椀挀猀 栀愀瘀攀 戀攀攀渀 䘀刀䤀圀伀ᤠ猀 攀砀挀氀甀猀椀瘀攀 唀䬀 瀀愀爀琀渀攀爀 昀漀爀 漀瘀攀爀 ㌀㔀 礀攀愀爀猀℀ 䤀昀 礀漀甀 眀漀甀氀搀 氀椀欀攀 琀漀 甀渀搀攀爀猀琀愀渀搀 眀栀礀 䘀刀䤀圀伀 栀愀瘀攀 爀攀洀愀椀渀攀搀 琀栀攀 瀀爀攀昀攀爀爀攀搀 挀栀漀椀挀攀 昀漀爀 洀愀樀漀爀 洀攀搀椀挀愀氀 洀愀渀甀昀愀挀琀甀爀攀爀猀 琀栀攀 眀漀爀氀搀 漀瘀攀爀 昀漀爀 愀氀氀 琀栀愀琀 琀椀洀攀Ⰰ 琀栀攀渀 瀀氀攀愀猀攀 挀漀洀攀 愀氀漀渀最 琀漀 猀琀愀渀搀 䔀㐀㜀⸀ 圀攀 眀漀甀氀搀 戀攀 搀攀氀椀最栀琀攀搀 琀漀 猀甀瀀瀀漀爀琀 礀漀甀爀 渀攀砀琀 瀀爀漀樀攀挀琀℀

㄀㐀㈀㌀ 㜀㤀㘀㈀㐀 栀攀氀氀漀䀀栀愀爀攀搀愀琀愀⸀挀漀⸀甀欀 眀眀眀⸀栀愀爀攀搀愀琀愀攀氀攀挀琀爀漀渀椀挀猀⸀挀漀⸀甀欀 匀琀愀渀搀 䔀㐀㜀

䘀刀䤀圀伀 簀 唀䬀


from The editor

I

[

Show me the way (to MTI Expo)

t seems like barely a year since I was last writing an editor’s letter telling you why you should come to Med-Tech Innovation Expo. Admittedly that’s because our last show was in September as we made our first steps towards living normally again following a pandemic only for a fuel crisis to come along and challenge us too, but we are back nine months later with Med-Tech Innovation Expo 2022. For those who regularly read this magazine, you might be familiar with a lot of what I’m about to say given our yearround Expo features in this title, and there will be plenty of column inches dedicated to what you can look forward to on the show floor and stages – and for those who have picked up this magazine in Hall 10 at The NEC or prior to your visit to Birmingham (and sorry to those who can’t make it), then welcome to the magazine that runs alongside the show. Of course, we haven’t been the only show in town. Just in April I had the pleasure, along with my colleagues, to head across the Atlantic to connect with many of you and others, at MD&M West in Anaheim. It was my

first time at the event, which may surprise you but much of my time at the helm here has been taken up by COVID-19 and lambasting government policy. Believe me, I don’t like doing that all the time, and it was nice that once we were able to step off our flights that we could remove our masks to talk about new projects, new ideas, what’s changed and how things may or may not have been reshaped thanks to the events of the last two-anda-bit years. Though we’re still recovering the pandemic it felt like the buzz was back as we met new and old faces – some fresh eyed into the industry, and others re-energised at our newfound freedoms and ability to put the ideas into practice that may have been sat on for a little while longer than was perhaps desired. I’m hoping for more of the same when we all meet on 8-9th June. This includes two days of insightful thought leadership across our two stages and a return of Pitch@ Med-Tech Innovation Expo as our budding start-ups compete again. You can hear from those on the show floor plus enjoy

more insights about the latest technological development on the Introducing Health-Tech Stage. Then on the Med-Tech Innovation Conference Stage you can hear about how we can tackle the NHS backlog, new manufacturing practices as sustainability becomes the buzziest of buzz words and as we have all become familiar with diagnostics and got used to Brexit… what next in both areas? I’ll look forward to seeing as many of you as possible when I host a live episode of The MedTalk Podcast which focuses on the current regulatory environment but if it’s not listening to me chairing a discussion with three distinguished panellists that floats your boat then why not connect with those on the Medilink Pavilion? Or one of our international pavilions from Italy and Mauritius? There’s also exhibitors from Germany, the Netherlands, Switzerland, the United States, Hong Kong and more! I’ve not even got onto the return of the Awards, yet! So, which way to Med-Tech Innovation Expo? That way!

5


Making medtech

Adapttech raises £2.25m and launches new range B iomedical start-up Adapttech has raised £2.25 million from investors including Mercia Asset Management, ACF Investors, Wren Capital, and Wealth Club. The company has also launched the new Insight Range, a family of products that make it faster and easier to fit lower-limb prostheses and improve patient outcomes. The new funding will be used by Adapttech to further develop wearable technologies to help people with physical limitations improve their quality of life. The company’s flagship product, the INSIGHT system, has been upgraded into a full product range, with several new options for O&P professionals, including:

Aquarate’s Hydracup used in the NHS Hydration Project.

A

quarate’s Hydracup has been selected to be used in four NHS regions to help improve hydration and reduce urinary tract infections. This hydration pilot will be implemented amongst elderly patients across a range of care homes, domiciliary care, and acute care settings. By introducing digital innovations across such a broad range of care settings, the impact of the Hydracup can be measured comparatively, allowing the areas with the greatest potential to be scaled up subsequently. CCGs and ICSs are looking primarily to reduce UTIs and decrease dehydrated related hospital admissions, but monitoring fluid intake has many more advantages. Monitoring fluid intake allows care givers to proactively adjust care given to avoid dehydration, confusion, dizziness, trips, falls & fractures, kidney issues and can reduce the need for antibiotics.

6

• INSIGHT Sense: a portable, and standalone realtime analysis pressure measurement system; targeted at smaller O&P clinics to reduce hardware costs and help them provide house calls.

Frederico Carpinteiro, CEO, Adapttech, said: “With the new INSIGHT Range, we’re responding to requests for a scanner-less system, reduced hardware costs, and improved data collection. This new

• INSIGHT Digitizer: a standalone digitiser for prosthetic sockets that creates high-resolution 3D models; targeted at central fabrication and large O&P clinic groups.

funding comes at a time when we are developing exciting new technologies to benefit our O&P clinic customers and their patients. We look forward to continuing our trajectory in growing our revenues, product portfolio, and international business operations.”

• INSIGHT Pro: combines both the INSIGHT Digitizer and INSIGHT Sense; targeted at larger O&P clinic groups, central fabrication, and research facilities and universities.

ClearSky develops MCI diagnostic C

learSky Medical Diagnostics has developed an intelligent medical device that can objectively diagnose mild cognitive impairment (MCI), a condition often suggested as an early stage of dementia. It is estimated that 5-20% of people aged over 65 have MCI, characterised by minor problems with cognition, such as memory or thinking. ClearSky MD is a University of York spinout company that develops non-invasive medical devices for the diagnosis and monitoring of neurodegenerative conditions, including Parkinson’s and Alzheimer’s. Its prototype diagnostic device – MCI-Monitor – is worn by a patient while undertaking a standard clinical test known

as ‘the reach and grasp task’. The kinematic characteristics of reach-to-grasp actions and the visual attention while performing the task are captured by the MCI-Monitor and measured using AIpowered technology. Software based on unique biologically inspired computer algorithms provide an immediate result based on quantitative measurement of the patient’s visuospatial ability, memory, and executive function - three important cognitive functions. ClearSky’s initial studies have suggested that MCI-Monitor is able to differentiate between Parkinson’s with normal cognition, PD-MCI (Parkinson’s Disease MCI) and PDD (Parkinson’s Disease Dementia). Professor Stephen Smith, founder of ClearSky Medical

Diagnostics, said: “We are excited about the potential of MCI-Monitor to replace timeconsuming and subjective conventional clinical tests to assist healthcare providers in making a diagnosis early, easily, and accurately. “We’ve already applied our specialised ‘white-box’ machine learning algorithms across a number of devices to help diagnose and monitor neurodegenerative conditions, such as Parkinson's and Alzheimer’s, and would love support to accelerate the development and testing of MCI-Monitor.” The company is seeking partners to collaborate on launching MCI-Monitor to the general population and is looking to achieve its third CE-marked product.


Expo News

Rebekah Jordan picks out a few products and services that will be showcased by exhibitors at Med-Tech Innovation Expo, taking place on 8-9 June at The NEC, Birmingham.

Guardtech to display laboratory and cleanroom products and services The Guardtech Group will provide its controlled environment design & build solutions, as well as cleanroom-related products and services at Med-Tech Innovation Expo 2022. Guardtech will also include its furniture & equipment, along with its contracts in facility servicing, maintenance and decontamination, across the life sciences template.

The Group’s five divisions deliver high-performance custom cleanroom design and construction: • Guardtech Cleanrooms – modular controlled environments and laboratories with custom cleanroom design. • Isopod Rapid Cleanrooms – standardised models with ‘flat-pack’ delivery and optional self-assembly installation.

• Cleanroom Solutions – high-quality controlled environment design & build services, for larger turnkey construction projects. • Isoblok Pre-Fabricated Cleanrooms – pre-configured, plug-and-play pods. • CleanCube Mobile Cleanrooms – for quick turnaround projects, space utilisation and temporary applications.

You can find out more about Guardtech's products by visiting Stand G37.

Unipart to showcase digitalised supply chain solutions Unipart Logistics will demonstrate its digitalised solutions and consultancy services, that sustain performance across medical devices at Med-Tech Innovation Expo 2022. Unipart supply chain solutions utilise machine learning and predictive analytics to improve sale forecast accuracy and realtime visibility to deliver multi-channel fulfilment. Additionally, its warehouse solutions are ISO13485 accredited, backed up with digital technology and data science solutions, that combat the challenges facing the healthcare sector. Their capabilities across the life sciences sector continue with: • Digital supply chain solutions - span data science, IoT and sensors, picking solutions, robotic process automation, 3D scanning and printing and augmented and VR. • Inventory optimisation uses predictive technology, big data, and machine learning to maintain the optimum balance between stockholding and service. Able to forecast demand

and automate stock replenishment decisions to reduce inventory and improve availability for endusers. • Kitting and customisation scalable and compliant with industry and temperature control regulations. Full service kitting, co-packing, and fulfilment services to support enterprise and direct customer requirements. • Precision tooling and fixturing - mechanical engineering for precise tooling and fixturing solutions. Metlase offers quick-make laser-cut prototype, production grade fixturing and tooling for manufacturing solutions. You can find out more about Unipart's products by visiting Stand E40H.

iVis exhibit suite platform of corneal surgery medical devices iVis Technologies will present its low invasiveness treatments and customrefractive medical devices for therapeutic corneal surgery at Med-Tech Innovation Expo 2022. The iVis Suite will include its comprehensive, refractive products of medical devices across the life sciences sphere: • CIPTA - software that optimises patient’s quality of vision and minimises surgical invasiveness. Incorporates a variablewidth transition zone to maintain linear variation of the corneal curvature, minimising risks of regression. • iRes – high-resolution, custom-refractive and therapeutic laser, delivering micrometric spots for smooth corneal ablations in one-step, controlling the

plume effect and preventing thermal damages. • pMetrics – dynamic pupil assessment - accurately defines the optical zone of ablation, based on ideal pupil computation and accounting for anterior chamber depth; minimising treatment invasiveness. • Precisio – high resolution tomographer - HD morphological and refractive maps and ID data for eye registration. Linked to the iVerify application which grants an automated and objective debriefing process, allows clinical follow-up and analyses corneal surgical outcomes. You can find out more about iVis's products by visiting Stand E10. Register to visit at www. med-techexpo.com.

7


CLEAN

21347-adv_MEDICALE_novemberENG.indd 2

02/12/21 09:22


MEDILINK

Footfalls and Heartbeats highlights smart fabric manufacturing process

F

ootfalls and Heartbeats has recently published a paper in the MDPI Engineering Proceedings, highlighting its technology as a viable alternative to the industry standard method of data capture for movement patterns and biomechanics. Footfalls & Heartbeats has developed a revolutionary and proprietary process for manufacturing smart fabric. Nanoscale interactions that take place within the fabric remove the need for wires or solid-state electronics; 'the textile is the sensor'. The paper, published by Footfalls, entitled: “Assessing the Validity of a Kinematic Knee Sleeve in a Resistance-Trained Population” is the first written by Nathan Toon, a recent graduate of Derby University who joined the company in September of last year. The study assessed the validity of a Kinematic Knee Sleeve (KiTT), designed, and manufactured by Footfalls, against Vicon, an industry leading, gold-standard motion-capture system.

Motion-capture systems are capable of recording joint angles such as the relative knee angle in the sagittal plane, the displacement of segments, and the angular motion of joints and segments. Relative Knee Angle is commonly measured when assessing squat depth to provide the user and coaches with information relating to range of motion or strength improvements that can be used to develop effective strength and conditioning strategies and rehabilitation plans. However, when recording motion through such systems, real-time data is not available, compromising the data’s value during a particular session. Additionally, these systems are not as accessible and are coupled with the need for specialist equipment and training. Wearable sensors that can be worn away from specialist settings and provide real-time and instantaneous data to users and coaches allows exercise or training methods to be adjusted

Cellomatics wins Queen’s Award for Enterprise C ontract research organisation (CRO) Cellomatics Biosciences has been recognised with the Queen’s Award for Enterprise for International Trade. Cellomatics is one of 225 organisations nationally to be recognised with a prestigious Queen’s Award for Enterprise. Employing 15 people, Cellomatics was founded in 2015 and specialises in the development of bespoke bioassays across numerous therapeutic areas including oncology, immuno-oncology, immunology, inflammation and respiratory. Last year, the company reported year-on-year organic growth of 30% since it was founded, in the wake of increased demand for its bespoke preclinical and early discovery phase laboratory services and expertise. The company’s exported business has increased over 15-fold, with export sales now representing

instantly, suiting the needs of the session to aid performance and rehabilitation in a way that is not possible with fixed and specialist motion-capture systems. Previous wearable sensors, such as smart watches focus on comfort for the user, rather than the quality of data. As a result, accuracy is often lost, leading to unreliable and invalid data. Footfalls and Heartbeats Kinematic Knee Sleeve (KiTT) aims to bridge the gap between comfort for the user and the collection of valid, accurate and actionable data. KiTT is a custom-knitted smart wearable knee sleeve, which is the first of its kind that knits the sensor directly into the fabric. Part of the KiTT is an electronics module, allowing data from the textile strain sensor to be transmitted to a portable device. Through comparing their KiTT technology against Vicon, it was found that The KiTT appears to serve as a practical alternative to Vicon without sacrificing the quality of the data.

approximately 50% of total revenue. Significant growth has come from clients based in Europe, Asia, and the USA. Cellomatics’ CEO and founder, Dr Shailendra Singh, said: “It is an absolute honour to be recognised with the prestigious Queen’s Award for Enterprise and for our excellence in international trade, particularly on the year of the Queen’s Platinum Jubilee. “Cellomatics has continuously moved from strength to strength since our inception over six years ago. We’re proud to have successfully completed over 200 projects in collaboration with approximately 70 clients in the last six years, with between 10 and 15 new clients secured each year, and around half of our clients placing repeat business. This has translated into strong revenue growth from an expanding international and diversified customer base.”

Nathan Toon, postgraduate researcher at Footfalls and Heartbeats and lead author of the paper, said: “I’m very excited to have my first manuscript published with the MDPI Engineering Proceedings. I hope that it will be the first of many, with the great supervisory team here at Footfalls and Heartbeats. Our findings show that Footfalls’ KiTT technology fulfills a real need in the field of sports science and rehabilitation and performs as a viable alternative to the industry leader.”

Rapid Fluidics strikes collaboration with Life on a Chip

R

apid Fluidics and Germany-based Life on a Chip have announced a collaboration agreement between the two consultancies. This brings together advanced skills in microfluidic design and rapid prototyping to serve clients developing microfluidic systems. With the combination of microfluidic expertise and next-day turnaround microfluidic prototyping, this collaboration allows customers developing point of-care diagnostics, organs-on-chip, or microfluidic detection devices to save time and money as they develop a working system. The partnership also allows both companies to leverage having a base in both Germany and the UK.

9


MEDILINK

A FRESH LOOK

Med-Tech Innovation News caught up with newly appointed Medilink Midlands chief executive Simon Himsworth to discuss his vision and the challenges likely to be faced by the company and life sciences as a whole in the immediate future.

C

ongratulations on the new role, but first if you could introduce yourself to our readers? Thank you. For the past 6.5 years I’ve been working with global biopharma organisations, helping them to solve industry-wide common challenges, and delivering industry-wide transformation programmes. Pre-pandemic it meant a lot of travelling globally, primarily in the U.S. and bringing knowledge and experience across the globe together to solve common industry-wide problems affecting all organisations and their respective supply chains. I’ve spent over 25 years leading the design and delivery business support and other organisational change programmes in both the public and private sectors. Before working in a global role, I’ve worked extensively in both the East and West Midlands and it’s great to be returning to my home region, and to continue working within

10

life sciences. I’ve been made very welcome within Medilink Midlands and I’m looking forward to leading the organisation into its next chapter. A new CEO inevitably comes with a new vision, what ideas can you share with us that you have for Medilink Midlands? Medilink Midlands has been a great champion to the life science sector and has shown remarkable resilience over the years, adapting to changes whilst maintaining the quality support for the sector. I want to see Medilink Midlands maintain that purpose and adapt to a new landscape post EU and pandemic. It’s very much about evolution not revolution, and I wish to continue our great work of supporting the industry and build on this with regional, national, and global partners across both the public and private sectors, by connecting and facilitating collaboration and industry support between academics, government,

businesses, and clinicians. What main challenges do you think the industry has to grapple with in the short-to-medium term? Coming new into the organisation, it’s great to be able to see things from afresh and from a wider perspective. One of my main missions in my first month as chief executive is to engage with key individuals and their organisations in the region to build up that wider picture and to listen to the needs of the region. Whilst there is the great opportunity for growth within the sector it needs to be supported by strengthening the technical workforce. The task of upskilling our existing workforce whilst continuing to nurture the next generation of STEM talent, will be a challenging one; which requires a collaborative approach from across the industry and government. The big challenge that isn’t going away is Brexit and the issues


Medilink

It’s very much about evolution not revolution, and I wish to continue our great work of supporting the industry and build on this with regional, national, and global partners across both the public and private sectors around supply chain and export and divergence between EU and UK regulatory systems. Companies are currently left to figure this out themselves with no clear answers and it’s going to be some time before things settle down. Client goodwill is at stake for many companies. Coupled with the rise in energy and raw material costs, we may see companies struggle. This presents an opportunity for us, ensuring we are at the forefront of delivering direct support to our industry. What challenges do you identify specific to Medilink Midlands that are high on your priority list to tackle? The key challenges for Medilink Midlands are continuing to champion and support our membership base and the wider regional life sciences industry amongst an uncertain funding landscape. We have the skills, the knowledge and expertise to deliver fantastic industry support and engaging thought leadership. We have seen how crucial this sector has been during the pandemic, and we need to ensure that as EU structural funding ends, life science companies in the Midlands are supported to continue their world leading research, development, and innovation. Therefore, high on my priority list is engagement with national and local government and industry thought leaders to ensure that the necessary support and correlating funding continues to flow into the sector. As an organisation, we now have formed one team that brings representation right across the Midlands. I’m working with my team to ensure that we are able to cross-pollenate our sector knowledge and experienced advisors so that all corners of our region benefit from the best insight and knowledge, and that we can deploy specialist skills and our resources to where it is needed in every part of the region. We will continue to be the regional delivery organisation to the life sciences sector, with specialist deployable advisory and events teams.

We will continue to look at the specific needs for each of our clients and activities, ensuring that they are locally relevant and address priorities; one size may indeed not fit all. The delivery of our support will be able to be more flexible, our connectivity and insight will have further reach, and our membership value will be increased. The last couple of years have seen many changes, notably with COVID and Brexit, what changes have you seen that the lay person perhaps won’t have done with life sciences? COVID has brought the life science industry to the forefront. It has highlighted the importance of this sector and the impact that many Midlands based companies have had on the pandemic response; utilising the expertise, knowledge and skills of region support the NHS. Speaking with the many stakeholders across the Midlands as part of my introduction as chief executive, it is clear that both the skills agenda and the digitisation of services and technologies has accelerated in order to respond to the pandemic and has highlighted its importance for the future; but has really only scratched the surface of what is possible. Therefore, it is essential to build upon this to ensure we remain at the forefront globally.

that we are likely to see a reduction in the amount that is currently available. How we fill that funding void will in turn affect how Medilink Midlands is able to provide the business and innovation support that has proven so vital to the region’s life sciences industry. So, my key priority, is to understand that funding landscape and to secure the continuation of that support for the sector. Is there anything else you’d like to add? In summary, the focus of Medilink Midlands will be to evolve our support, events, and membership offerings, which will bring greater value to the region by being able to deploy multiple specialisms across the whole region to where they are needed. I am looking forward to growing our membership offering and for it to become a 'must have' for a medtech business with a base in the Midlands. This will enable us to continue to support our medtech and life sciences partner organisations, their innovations, commercial activities and general 'licences to operate' within a highly regulated and complex sector. It will enable us to our expand our voice of the industry back to central government, particularly The Office for Life Sciences, regional government, the NHS, academia and other valued stakeholders and partners. Contact Medilink: info@medilinkmidlands.com www.medilinkmidlands.com

Though the UK left the EU in 2020, there has been this almost transition period where the last of the EU funding grants can be spent in the UK, how big a challenge is securing funding to replace that, both for you as a company and for your members? As ERDF ends, replacement sectoral focused business support that accelerates and supports innovation, particularly into the NHS, is still unclear. What is emerging is

11


on the cover

Going beyond borders - AN ITALIAN FEEL TO MED-TECH INNOVATION EXPO

T

his year’s Med-Tech Innovation Expo will have a slightly different feel to the last year. Not simply because of us all having greater experience of live events prior to the last outing, but with a strong Italian presence providing even more of an international feel to this year’s exhibition. When explaining one of the main reasons for the decision to exhibit with such a large presence at Med-Tech Innovation Expo, Filippo Mansani from the Italian Trade Agency pointed to the established relationship between the UK and Italy when it comes to trading and co-operation in life sciences. “If you look at the net exchange between Italy and the UK, one of the most prevalent things that you see imported and exported between us is pharma, medical and machineries. “Medtech is one of the primary sectors for the Italian ecosystem and in our exports, especially to the UK. We have a really mature ecosystem in Italy in medtech.” As part of this ecosystem, Mansani highlights the work that goes on in research and development from universities, and the many spinouts that emerge from these institutions. Mansani also identified that the willingness to visit this year’s show from so many companies shows an eagerness to expand beyond national borders. “We have several clusters around the main corporates dealing with the pharma and medical sectors. “They look at the UK as one of the main markets to start exploring potential collaborations with local partners.” The 18 companies accompanying the Italian Trade Agency come from across the sector attempting to address different needs and may also have different aims as to what they want to achieve from their Expo experience.

Ian Bolland caught up with Filippo Mansani, head of innovation and high-technology capital goods at the Italian Trade Agency to find out more about its visit to MedTech Innovation Expo, along with 18 companies making up the Italian Pavilion at this year’s show.

12

“It’s going to be different for every company. Some of them are more well-established so I guess their target is more towards potential clients or partners, and those at the early stage might be looking more towards investor partners.” Four start-up companies, for example, delve into different areas. One focuses on the development of miniaturised devices to help urinary incontinence (UI), another company iVis is looking for a strategic partner to help expand its 4D Suite platform used for corneal refractive and therapeutic surgery, as


ON THE COVER

Medtech is one of the primary sectors for the Italian ecosystem and in our exports, especially to the UK. We have a really mature ecosystem in Italy in medtech well as companies that can do ad-hoc production. The start-ups within the Pavilion demonstrate the broad range of what Italian medtech has to offer. All the companies have brought at least one product to market in different fields. Specialisms include packaging, sterilisation, connecting manufacturers and distributors, infection control and many more. The COVID-19 pandemic saw an urgency for certain types of medical devices and technology and Italy was no different with Mansani saying it helped accelerate the transformation of ideas into products – especially when it comes to digital health. Referring to the sector in Italy, Mansani again alluded to the ecosystem and ideas emerging from the universities, but also the state support and initiatives that are available. “We share research centres and the market is growing. We have really important applications for several cross-sector activities and functions within the medical, pharmaceutical and life sciences space. “We have new funds that the government has launched during the pandemic which is also boosting venture capital. There is even more attention on the investment and corporate side and a willingness to implement new trends and new technology.” The Italian Trade Agency has also been supporting the companies with brokerage events so they can make new connections and establish new deals and partnerships. Coming to Med-Tech Innovation Expo is an opportunity for the companies to do some good quality networking, something Mansani points out when asked what would make a successful

show for the trade body and its accompanying businesses. “These companies are looking to network and to explore new trends and how the market, especially in the UK, is moving on. Mainly it’s all about networking and exploring new trends.” Mansani also alluded to every region in the country having the capability to foreign direct investment strategies to attract new talents and new incentives to do business in the sector. Explaining the possible incentives, Mansani said: “For example, these can be start-up visas or definite investors in your company that are incorporated in one of the regions in Italy.” He explained that similar schemes were on offer in the UK such as International Collective and Enterprise Investment Schemes. When alluding to the outlook and challenges faced by companies in the sector, Mansani focused on the outlook for Italian start-ups and their challenges when it comes to securing investment and highlighted one particular obstacle. “In Italy funding is available until Series A fundraising and then companies need to explore funding avenues, opportunities, and partnerships elsewhere after that.” As well as having the opportunity to meet with several companies from Italy, visitors will also have the opportunity to hear from the Italian Trade Agency about new trends from the country and how to access the market on Stand E10. Med-Tech Innovation Expo takes place on 8-9th June. You can register at www. med-techexpo.com.

Featuring on the Italian Pavilion are: • Hakomed Italia • MWC • LED Spa • Relief Srl • Senosan • Fifth Ingenium • Viktor Elettromedicali & Physio • IRCA Spa (Zoppas Industries) • Endotics • Ecs Srl • Ric3D Srl • DM Packaging Group • AMD Engineering Srl • 1Flex Technology • Food4Future Srl • Ivis Technologies • Biochemical System

13


Your Midlands Life Sciences industry association with a vision

to stimulate the growth of the Midlands

life sciences sector by helping companies establish, develop and grow.

We work with our members so that they

BUSINESS SUPPORT

can protect their licence to operate. FUNDING & FINANCE

Our sector; from multinationals to high potential start-ups, as well as the NHS and

OPPORTUNITIES

Universities. Working alongside the Midlands Engine and other strategic alliances, Medilink

EVENTS

Midlands helps stimulate additional and value-added growth of the Midlands as a prosperous community for Life Sciences.

ACCESS TO THE NHS

Medilink Midlands in numbers

6,500+ Contacts in our network

2,300+ 48% Organisations

info@medilinkmidlands.com

www.medilinkmidlands.com

FIND US @Medilink-Midlands @MedilinkMids

of our membership are MedTech


Sustainability

Why sustainability is vital in the future production of medical devices

Barry Warden, managing director, Wideblue, runs through several of the sustainability considerations required for a medical device company.

S

ustainability is an issue that as medical device developers and manufacturers we need to embrace, but it is not straightforward. We need to realise that future profitability will be linked to sustainability. From the beginning of the design process, manufacturers already take many factors into account, and now must consider sustainability. When considering medical device sustainability, often people think about the end of the lifecycle and whether the device is recyclable. Also, what are the costs involved, and downstream environmental impacts associated with disposal? Medical device waste is a global problem as devices become more complex and incorporate more electronic components and mixed materials. Sustainability also means reducing carbon emissions, energy and water use, and material waste across its entire lifespan. Sustainable medical devices are better for the environment and attractive to consumers and can provide cost savings, investor attractiveness, and improved brand and competitive advantage. As medical device designers we have been working to respond to the increasing demand for environmental sustainability from the market while ensuring that safety and usability to healthcare workers and patients is at the top of our priority list. MATERIALS According to the UK Government, plastic waste in the oceans may treble within the next decade. Everyday single-use plastics can take

over 400 years to biodegrade. Medical device manufacturers need to investigate using more sustainable and different materials in their equipment, such as reusable plastic biobased material. With net zero targets in place and environmental sustainability now an important priority for medical plastics and device manufacturers and their supply chain, the industry is now moving in a new direction, that of a sustainable and ecofriendly plastic product, or reducing the number of and swapping materials in the make-up of devices Taking sustainability issues into account in the design stage does make for a challenging process, but the rewards will come both in terms of the environmental impact of your products and ultimately in profit. DEVICE DESIGN As designers and manufacturers, can we reduce the dimensions or weight of the product to minimise materials used? Can we shrink electronic components to reduce their disposal impact? Is there an opportunity to reduce the battery size, switch to a more sustainable battery technology, or alternative energy storage methods?

the technology built into a smartphone to bring eyecare to low-income communities. Using existing technology, rather than developing this from scratch, reduces cost and the product’s impact on the environment through reduction in raw and processed materials. MANUFACTURING PROCESS The production process should also aim to be ecofriendly. Always consider what manufacturing options are open to you, and whether you could reduce energy and water use. Reviewing the manufacturing processes plays an important role in reducing the environmental impact of production. New manufacturing technology can also help reduce waste, whilst improving productivity and shortening time to market. Having a sound understanding of where energy is used within the design and production of your device is key to reducing the long-term environmental impact of your product. PACKAGING Packaging has huge environmental implications and is an area where most companies are now really trying to

cut back. We are always asking ourselves how packaging waste can be minimised, and if recyclable or compostable packaging materials can be used? We are also moving from paper-based documentation to on-device wherever possible. DISTRIBUTION Distribution is important when you are trying to lower your carbon footprint but represents big challenges, especially with exports. Things to consider include manufacturing and warehousing locations that can minimise long-distance transportation and using electric vehicles. DISPOSAL Efforts to reduce the volume of disposable components are constrained by the need to maintain safety standards. The risks associated with hazardous medical waste and biological contamination, as well as the high cost of product sterilisation and reprocessing, have prevented many businesses from moving away from disposable products. However, more must be done to transition from single-use devices to more reusable devices, and materials need to be used which can be recycled or degrade naturally.

Generally, most medical devices are now getting smaller and smarter, which helps with sustainability issues. One reason medical devices are shrinking is because they are being designed for mobile applications which requires the integration of wireless technology, making them more portable. Our Peek Retina ophthalmic device harnesses

15


Med-Tech Innovation Expo

Back with a bang Nine months following its return after the spate of COVID-19 lockdowns, Med-Tech Innovation Expo returns on 8-9 June, and Ian Bolland picks out a couple of things to look out for at the 2022 running of the event.

A

s part of Manufacturing Week at The NEC, Med-Tech Innovation Expo is a great environment to come across new technological developments, trends, product demonstrations, and that opportunity to make those all-important new connections and leads. With over 100 exhibitors, three pavilions, two conference stages, and a start-up zone, it means there will be plenty of activity on the show floor across the two days. The companies vary from those specialising in injection moulding, packaging, consultancy, materials innovation, distribution, and logistics allowing for everyone across the sector to make the business connections you require.

Here’s a few things I am looking forward to: PRODUCT DEMONSTRATIONS As the show connects the entirety of the design to manufacture supply chain, the show floor will cover of a full range of materials developers, manufacturers, device developers, but also products that are required to operate in the manufacturing environment. Packaging specialist Shawpak (Stand C25) will be bringing along its 4-side seal packaging machine. Manufactured at its facility in Derby, the company says its 4SS-6030 machine incorporates the latest technologies and functionality to ensure high efficiencies and low maintenance. This is also the first Expo the company has decided to showcase the machine on a show floor.

16

The aptly named Shoe Cover Magic (C20) will be bringing its own little bit of wizardry with its shoe cover machines – where you can simply place your foot in right area for the machine to add and remove covers. At a time when infection control has never been talked about more, this kind of offering is useful for the cleanroom environments and adds that extra layer (literally) of infection security. Speaking of infection control, one company where this will be a core focus is BioInteractions (B5). At the recent MD&M West show in California, the company launched TridAnt, a new coating technology for medical devices which it says presents a shift in infection protection against a broad range of pathogens. You can hear more about this product and more about infection control with medical

devices from BioInteractions’ commercial director Arjun Luthra who will be delivering a seminar on Day 2 on the Introducing Health-Tech Stage. Speaking to Med-Tech Innovation and Medical Plastics News at MD&M West, Luthra says the company’s latest technology kills a minimum of 99.999% of germs and compared the company's drive to develop antimicrobial technology to that of Formula 1 racing. He said: “The faster you are or the more elite while you're fighting for the smaller little minuscule or seconds. It’s the same thing. We're fighting for the one in a million or one in a hundred million. We're fighting the one in a hundred billion. It's really changing the likelihood that a pathogen will likely be there in that environment.”


Med-Tech Innovation Expo

CONFERENCE STAGES Luthra’s talk is just one of several insights that you can expect across our two conference stages, as he addresses infection prevention measures and associated healthcare infections. The Med-Tech Innovation Conference Stage in association with Medilink UK brings together a programme covering the pressing issues affecting the industry today – ranging from new potential in manufacturing, how the pandemic has affected approaches to innovations, building a technology ecosystem in social care, helping to combat the backlog in the NHS and, of course, the topic of how to maximise potential in international markets.

That’s not all, as I’m particularly looking forward to hearing from the Day Two Keynote speaker, Karen Taylor from Deloitte, who has led research into the changing face of diagnostics and will present some findings as part of her seminar surrounding innovation in this part of the sector.

With over 100 exhibitors, three pavilions, two conference stages, and a start-up zone, it means there will be plenty of activity on the show floor across the two days On the Introducing Health-Tech Stage, sponsored by Hessen Trade & Investment, there will be a mix of those who are exhibiting on the show floor as well as compelling talks about developing innovations during the recent pandemic and bringing products to the NHS. An esteemed panel of guests will discuss the pressing regulations in the medical device sector and how they are going about navigating that environment. The afternoon of Day Two will see the return of PITCH@Med-Tech Innovation for the second successive year, brought to you by NIHR, SBRI and Innovate UK – where several budding start-ups will compete against one another in quick-fire sessions as they showcase their innovations and why they feel they have the potential to have a lasting effect on the health service, and develop further as a company. You’ll be able to read an interview with the winner in the next issue of Med-Tech Innovation News. PAVILIONS AND ZONES The international feel to the show this year will be a big

highlight, as you’ve no doubt picked up on in my Editor’s Letter. A mainstay of the Expo is the Medilink Pavilion and that returns once again, populated with exhibitors from their membership while the aforementioned PITCH contenders will feature on the start-up zone – giving visitors the opportunity to find out more about their exciting ventures away from the spotlight. This year also sees the international feel of the show expanded as the Italian Trade Agency is accompanied by 18 companies from the sector to make up the Italian Pavilion – while the Economic Development Board of Mauritius returns to the show after its most recent visit in 2019, bringing along three medical device companies. The international feel doesn’t just stop with the Pavilions as companies from The Netherlands, Switzerland, Germany, the United States and Hong Kong are among those who have a presence on this year’s show floor.

FOR MORE INFORMATION AND TO PLAN YOUR EXPO EXPERIENCE WITH OUR EXHIBITOR PORTAL, VISIT WWW.MED-TECHEXPO.COM

17


Innovative Automation Solutions from R&D to Certified Manufacturing VISIT US AT B13

Medical Devices

Microfluidics

Biosensors

Lateral Flow

Local Technical Support and Healthcare Packaging Design Meet us at Medtech Innovation Expo 8-9 June, NEC Birmingham, UK

STAND C17


How, What and Who: Does the medtech sales model need a rethink? Oli Hudson, content director at Wilmington Healthcare, looks at challenges in the current medtech sales model – and a possible route through them.

Many clients are coming to Wilmington Healthcare with the same set of issues – restricted access, time poor staff, an inability to carry out demonstrations and evaluations in the same way as pre-pandemic times. The reasons for this are hardly opaque; the NHS is suffering from four deepseated challenges; dealing with the care backlog; a workforce crisis; changing the structure and delivery of healthcare via integrated care models; and responding to a new efficiency drive which gives an overall annual savings target 2.2% this year – up from 1.1% in the previous one - to save £4.75 billion. This means clinicians are taken up with the caseload before them with little time to evaluate or gain evidence for innovation; procurement departments are trying to find in-year savings; and the process of contracting varies from system to system. Theoretically, new procurement models as mandated by NHS England should allow for aggregate purchasing, greater spending power and longer term investment, a recent article by my colleagues at HSJ has shown that these are in the forming stage. At system and local level, there is a mixed

picture on leadership in terms of procurement. While much more collaboration is happening, individual trusts still act independently upon their own protocols and there is still no ‘one way’ of seeing the purchasing and procurement process. Also, a new paradigm of working digitally, and a general digital first trend in terms of preferred engagement routes for stakeholders, and medtech is left with some big questions on what to do next. HOW AND WHAT: OMNICHANNEL AND TAILORED CONTENT Some medtech companies are adopting a different approach – one that is both hybrid face-to-face/digital and tailored. Rather than relying on just call volume and field work, content and comms are taking a more central place. Omnichannel marketing – involving companies accelerating their digital approach and adding selfservice portals, webinars, microsites, and social-media content— is supporting remote interactions with both HCPs and nonclinical stakeholders. Omnichannel is becoming the preferred engagement technique. And, most companies are equipping their reps with virtualcommunication tools and digital content and training them in remote selling. But at its heart it demands tight customer segmentation and compelling content to suit - and in this, medtech

is still developing its approach. It will be important to vary content and comms to suit audiences at strategic/ system or place level, and by customer type, for example clinical, commissioner, or procurement. A series of articles by my colleague Simon Grime – written with pharma in mind but just as applicable to medtech - covers this in more depth. He says: “The goal needs to be a genuine and continually enriched 360-degree view of each individual customer, covering their stage of engagement, their preferences, their previous behaviours, and touchpoints online and their engagement with different content types. It requires comprehensive and fully integrated data which paints a picture of the customer as an individual and responds to them as such.” This research should include analysis of local demographic data – especially health inequalities, the local population health picture, and how new techniques and products can address them. On content, compelling patient stories are also becoming more popular and Wilmington Healthcare has been involved in the production of these, in one case helping to move a minimally invasive heart valve replacement technique into the mainstream by using illustrative narrative. WHO: STAKEHOLDER MANAGEMENT So, if omnichannel and hybrid F2F/digital working represents the how – and

compelling exchange of value and relevant content the what – where does that leave the who? Here, research into the marketplace is equally necessary. New NHS policy stresses the centrality of clinicians in the decision-making process – in changes to pathways, setting, technique and procurement. The GIRFT programme is proving influential as a clinician-led, bottom-up approach to reducing variation and improving standards of care – as well as accelerating innovation adoption. Simply, it is clinicians that are most important to convince and empower. Research is also needed into how clinicians are grouping themselves – into clinical networks for example, or into hub-and-spoke models – and are taking amendments to pathways forward. Another group of stakeholders charged with assisting industry are the AHSNs, who should be able to assist clinicians develop business cases and overcome obstacles to adoption. The 15 AHSNs should be on the radar for innovation, particularly for NICE approved products that have already earned their place in therapy via clinical and cost-effectiveness and to enhance the evidence base. Each system and place will throw up clinical champions for therapy areas and surgical techniques. Somewhere in the overlapping networks of clinical influence and accountability, there will be those capable of enacting change with access to transformative power. It is these such individuals that medtech must engage.

19


Cross Manufacturing Precision Sealing Solutions

 Components for prosthetics, surgical tools and equipment.  Manipulation of metal forms in a wide range of superior materials.  World class quality.

Contact us today!

Remove bottlenecks and simplify your processes

Make your adhesive and dispensing processes more productive with process-optimising materials & systems • Improve speed and accuracy • Get fast, homogenous mixtures of dispensing with dedicated of liquids, powders and pastes dispensing robots with mixing and degassing machines • Reduce work in progress with fast UV light curing materials • Achieve more consistent • Improve process simplicity with bonding results with plasma process-convenient materials surface treatment packaging

Could you reach your productivity potential by improving some of these areas? Read more at intertronics.co.uk/productivity.

Cross Manufacturing Company (1938) Ltd www.crossmanufacturing.com

+44 (0)3301 224 400 | contact@crossmanufacturing.com

01865 842842 info@intertronics.co.uk intertronics.co.uk/productivity

Intertronics Process Improvement Qtr Page 124x86 ad


Microfluidics

S IC ID U L F O R IC M E R A Y H W IMPORTANT IN MEDICAL TECHNOLOGIES?

M

icrofluidics has been a rapidly growing field within a range of engineering disciplines over the past few decades, with applications running from thermal control of microelectronic devices to chemical process engineering, and even simple fluid-based computational logic! But nowhere has the precision control of tiny quantities of fluid found more uses than in the medical sciences. Thousands of centimetre- or even millimetre-scale devices have been developed for use in highvalue drug production, emulsion generation, cytometry, drug detection, drug dosing, cellular analysis, cancer detection, or a whole range of other specialised diagnostic applications. Microfluidic devices are characterised by the handling of very small quantities of fluid, either as continuous flow in a channel, storage in microwells, or as droplets on a chip; typical volumes range of femto- to picolitres (10-15 – 10-12 L)! Because the manufacturing processes for many microfluidic systems were originally developed in the semiconductor industry, they also lend themselves well to the direct integration of micromachined sensors and actuators: Labs-on-a-Chip! In diagnostics as well as pharmaceutical production, one clear advantage of a microfluidic approach is a reduction in the consumption of expensive reagents and catalysts (i.e. platinum, palladium, rhodium). Similarly, a reduction in the generation of waste products is desirable because handling may be non-trivial, either requiring complex and energy intensive processes for breakdown into nontoxic substances or specialised long-term storage. If microfluidics can reasonably be employed, costs may be reduced not only on the input and waste effluents, but also on other peripheral process factors

such as capital costs due to reactor modularity, energy efficiency, or better process control.

such as at the surface of catalyst particles in production or singlecell sorting in diagnostics.

Microfluidic platforms significantly increase the fluid surface-tovolume ratio, which provides a range of process-control advantages. One of these is rapid mixing; where two reagent streams come into contact, for example at a T-junction, complete and homogeneous mixing occurs on a far faster scale than in macro-scale mixing. In many applications this is critical because incompletely mixed reagents may allow undesired sidereactions to occur. Additionally, this rapid mixing plus the small channel size allows for a high degree of thermal control. Highly exothermic or even explosive reactions may be carried out safely because only a small absolute amount of heat is generated, and it is quickly removed. Consistent temperatures in the fluids leads to more consistent yields, whether in production or in diagnostics.

The physics of these multiphase microfluidic processes can be extremely complex! Generating the desired droplet or bubble size requires a lot of fine-tuning of channel shapes and sizes, as well as pressures and flow rates. Biological cells or catalyst particles may clump or stick to walls, forming blockages, so it’s important to understand channel and particle surface properties, and whether flow patterns will reduce adhesion and blocking risks.

While microfluidic platforms offer a range of safety, cost, and processcontrol advantages, there are challenges which remain topics of ongoing research and engineering development. One of these areas is in quantifying the effects of manufacturing tolerances. Because the channels are so small, deviations from a designed cross-section profile may have an outsized effect of factors such as pressure drop or mixing behaviour. Another area which often presents challenges is in multiphase flows. In microdroplet generators, two immiscible fluids meet at a junction, with highly repeatable droplet size distributions resulting; these are often used in emulsions for drug encapsulation and dosing. Similarly, microbubbles may be used for gas-liquid reactions that require extremely fast mixing. Solids entrained in a flow similarly allow for enhanced process control,

Because of the complexity of these processes, physical device manufacture and test can become expensive and time-consuming. Computational modelling, while not a replacement for physical testing, can greatly reduce development time and costs. Correlation of modelling results with existing experimental data can give confidence in the fundamentals of a baseline model and can then help accelerate new design iterations. Xi Engineering Consultants has extensive experience in Finite Element Simulation with COMSOL Multiphysics for a broad range of engineering applications, including microfluidics. Xi has been working on several medical related projects with the most recent one being LUMICKS (Amsterdam, Netherlands) on the design and characterisation of Lab-on-a-Chip devices incorporating acoustic cell-manipulation capabilities in microchannels for single-cell cancer detection diagnostics. Indeed, this is another medtech success story as we met at the 2021 show and began developing collaboration ideas since! Xi Engineering will be at stand B37 at Med-Tech Innovation Expo 2022. For more information visit www.med-techexpo.com.

21


Your technical experts for plastic injection moulding

DESIGN DEVELOPMENT MOULDING TOOLING BEYOND THE MOULD Make Pentagon your UK supplier of choice for Mould Tool manufacture and Plastic Injection Moulding. Whether you need a supplier for a new injection moulding project or sourcing a new manufacturing partner for existing production, Pentagon will support you at every stage.

www.pentagonplastics.co.uk | websales@pentagonplastics.co.uk Tel: +44 (0) 1403 264 397 |

Innovative solutions. Engineered to your specific requirements. Realize your vision. Partner with the most innovative team in the industry. MicroLumen.com


Testing & Inspection

EXPLORING THE VIRTUOUS CYCLE: TEST SYSTEM DESIGN

& DESIGN FOR TESTABILITY

Jason Swoboda, senior program manager at Velentium, explains why device test systems should be developed in parallel with the device itself, and in partnership with its designers.

A

s developers, we’re comfortable with the idea that design informs testing. However, design teams are often less familiar with the ways in which test system development can and should inform design. This concept is the basis for a key consideration in development called “design for testability.” This means considering what should be tested and why, as well as when and how those tests will take place, as early as possible in the development

1 FIRST, design the test system in partnership. Our team was tasked with creating a test system to put one element of a device through its paces. The product included a PCB with an onboard chip that drove a motor. Our system was meant to prove the motor would be able to do what the product needed it to do. To accomplish this, we designed a fixture that used digital communication to drive the motor using the same techniques as the control program inside of the end product. This meant we didn’t need to wait on the team creating the PCB firmware to perform motor tests. It also meant that we couldn’t be 100% certain that our test software would drive the motor in exactly the same way the device firmware would. We could have instead used an actual controller board from the product as part of the test fixture and exercised the functions of the motor using productionreleased software. It was a missed opportunity, and a lesson that if the test plan calls for testing an element of a product system, look for opportunities to incorporate related elements directly into the test fixture. That way, you can test the subsystem as a unit in addition to testing its individual components.

lifecycle. Test engineering will be able to do its best work by developing test plans and systems in parallel with the device itself, and the device design will be improved when principles of testability and findings are incorporated into the design. Here are a couple of principles, illustrated with real examples.

2 SECOND, just because it's measurable doesn't mean it's significant. Know your “why.” Test engineers get laser-focused on how precisely we can measure. Test systems have the potential to perform measurements far beyond what is truly necessary. Or there can be a sensitivity mismatch between the test fixture hardware and the DUT. On a high-pressure test system, we were asked to use a particular model transducer that senses up to 40,000 PSI and translates that to a digital signal with 0.25% resolution, meaning the transducer output readings are accurate to within 100 PSI. Yet the test protocol we received indicated that the client wanted us to perform a test where the DUT was subjected to 17,000 PSI and held there for a certain length of time, during which the pressure was not to fluctuate by more than 10 PSI. So, the test spec called for a transducer that is “only” accurate to within 100 PSI, but the test protocol demanded an accuracy of 10 PSI. This is a situation where test engineering needs to go back to the design team and ask some questions. What is truly required of this product? What must the test demonstrate? As Velentium’s CTO, Randy Armstrong, frequently advises: “Know your why.”

3 THIRD, design test systems for intelligent data capture and reuse from the beginning. Where automated test projects are involved, start logging all test data early and build functionality into the control system. This allows you to repeat tests using data “played back” from a prior test or set of tests, instead of always having to use a “live” DUT. Gathering the full testing data set allows test engineers to refine the control system for the test fixture itself. As soon as you know what the test inputs and outputs are, start logging. The design and test engineering teams can decide later on what’s valuable to continue collecting for feedback on the system. This approach provides the software and hardware development teams the capacity to test against specific scenarios that hadn't been considered before. When tests fail, it allows you to look back, DVR-style, at its cause. The hardest automated test problems to troubleshoot are often those that can’t be replicated for lack of data. By taking this approach from the outset, it builds an opportunity for continuous improvement of the test system, a great troubleshooting tool for test engineering and more granular insight into the DUT performance. By working in tandem from early on, design and test engineering teams develop more efficiently, reducing cost- and schedulerelated risks and leading to better final products.

23


Medtech | Digital HealthTech | Medical Plastics | Manufacturing | Software | Inspection and Metrology Regulation | Design | Early-Stage | Innovation | Pharmaceutical | Manufacturing

MED-TECH INNOVATION

7-8 JUNE 2023

NEC | BIRMINGHAM | UK

Exhibit with us in 2023

Medical Device Supply Chain Intelligence


Testing & Inspection

Remaining data compliant in the world of medtech Mike John, technical director of industrial metrology specialist The Sempre Group, explains how manufacturers in medtech can automate data collection to streamline compliance reporting and gain insights.

I

n the world of medical technology and healthcare, quality management is key. Manufacturers must comply with increasingly stringent regulations, such as ISO 13485: 2016 and ISO 17025 and be able to provide a fully traceable report that proves quality throughout the product’s lifecycle. Whether the device is a wearable blood pressure monitor or a drug delivery system like a metered dose inhaler (MDIs), ensuring reliability and safety is critical. The world of medical devices is just as stringent. Manufacturers must be 21 CFR Part 11 compliant, which means ensuring that all electronically generated information is fully traceable and free of gaps where human error can occur in data collection and introduce untraceable faults. This means keeping a trail of where data is amended, stored, transferred, or accessed.

THE FUTURE IS AUTOMATED Manual data collection is time consuming and lacks complete traceability, increasing the risk of human error because there is no guarantee that operators input data from one source to another accurately. By reviewing incorrect data, operators risk adjusting machinery unnecessarily, stopping production or allowing lower quality parts to pass inspection. Consequently, production levels are damaged, and parts become non-compliant, harming the manufacturer’s reputation. The production and quality process can never be fully traceable unless there is a digital thread connecting drawing to product to report. For example, a medtech developer could take notes of measurements

in a first article inspection (FAI) report and input the dimensions into an isolated Excel file that isn’t linked to the original ballooned drawing or future quality checks, making it difficult to guarantee that all parts meet specifications. Instead, the operator uses fully traceable automated data collection systems, such as High QA, to streamline FAI reporting. Another example is the Prolink SPC Data Collection Software, which, as well as being 21 CFR Part 11 compliant, allows manufacturers to extract real-time data from any device to enable full analysis and reporting. By using High QA, developers can scan entire drawings, or multiple pages, and extract the geometric dimensioning and tolerancing (GD&T) data and critical dimensions, with all the tolerances automatically allocated. Using this data, they can generate FAI, Production Part Approval Process (PPAP) and other reports, and store future measurement data in the same centralised system. A REFORMED INDUSTRY By using automated, real-time data collection software, those in the medtech industry can extract realtime data from any device to enable full analysis and reporting. Without relying on isolated documents, manufacturers can communicate important quality information to stakeholders and reduce the time needed for compliance reporting.

Analysing the reports provides medtech developers with full visibility over production quality processes, so they can demonstrate and identify areas for improvement. For example, if they notice that parts on a wearable device are not compliant, the report will say when the fault occurred and help them resolve the issue. Over time this will decrease the number of defective products, reduce material waste, and improve productivity so that healthcare facilities and other customers receive fully compliant parts and devices sooner. Medtech and medical device manufacturers can also use software and data to make proactive changes during production. For example, if a part does not meet specification, software like Reaction Plan Manager will instruct the operator on how to adjust the machine to correct the issue without needing a specialised engineer to assess the process. By adjusting tooling as soon as an issue is spotted, engineers can ensure that fewer parts are manufactured out of tolerance, reducing scrap. As the amount of data usage continues to grow exponentially, we need to understand how to make the best use of it. The same can be said for the highly regulated medtech industry — by analysing reports acting on the results, manufacturers can make the informed decisions that will improve efficiency, reduce costs, and ensure compliance. The Sempre Group will be exhibiting at Med-Tech Innovation Expo on Stand D13 on 8th-9th June at the NEC, Birmingham. For more information visit www.med-techexpo.com

25


DIGITAL HEALTH

SPONSORED BY

DRIVING ADOPTION

D

OF DIGITAL HEALTH INNOVATION IN 2022 Doug Biehn, chief commercial officer, Cala Health, highlights the key factors driving the adoption of digital health.

advancements. Because keeping patients – particularly those who are at high risk – out of in-patient settings is critical, it has allowed digital health to advance even more rapidly than before and picked up the pace significantly around adoption. Solutions that can tap into the growth in telehealth and related technologies stand to do well in this environment.

Digital health is in a perpetual state of innovation, with life-changing therapies, medical devices and more hitting the market daily. But what drives adoption of these innovations? Insurance coverage and reimbursement are often the main drivers, but before a digital health company can hit those milestones, where do they start? EASE OF USE AND VALUE A huge driver of adoption is ease of use for both patients and prescribers. Think about the devices we choose to buy and interact with in our daily lives. For computers, cell phones, and even cars, we wouldn’t bother to buy them if they were difficult or frustrating to use. When a digital health solution isn’t designed with the patient experience in mind, demand will be almost non-existent. We see this play out often with digital health technology because it can be extremely sophisticated and may contain complex technology. Despite that, keeping in mind ease of use for the end user (an often diverse range of patients and prescribers) is key to adoption. Although a new treatment option may be superior, physicians will not adopt or prescribe if it adds steps or complexity to their workflow. Physician and patient adoption are directly tied to the propensity of a Health Plan to cover and reimburse.

26

Ease of use is also strongly correlated with value. Overall, healthcare can be incredibly expensive, even after reimbursement, so showing that a treatment is being offered at a reasonable, affordable cost prior is key. Value goes both ways. If a new treatment is not affordable, then physicians will be less likely to adopt it and patients will not use it. Additionally, if a treatment is not affordable, then it is also perceived to be not easy by both

physicians and patients hence reducing the overall demand and adoption. THE TELEHEALTH BOOM Despite the many losses and human setbacks of the pandemic, one positive following the past two years of lockdowns is that they’ve enabled incredible advancements across industries. In healthcare specifically, we’ve seen rapid advancements in telehealth technology. Patients have learned the skills needed to improve safe access to healthcare services. We’ve also benefited from CMS’s expanded reimbursement for telehealth and similar virtual care options, such as remote patient monitoring and wearables. In the past, the creation of new reimbursement categories was slow-moving, but following the critical need for remote care, it has opened the door for a plethora of new digital health innovations to make significant moves towards adoption. The past two years have given the digital health industry not only an incredible proof point for developing treatments that can be monitored remotely, but nearly forced these

EMPOWERING PATIENTS A somewhat unexpected driver of adoption is the patients themselves. In addition to studies and other tangible information pointing to the success of digital health treatments, patients make up a portion of what makes digital health adoption possible. Today, patients are active participants in their healthcare and feel empowered to proactively ask about new treatments and therapies. This can be compelling enough for a prescriber to consider new options for their patients. New digital health solutions need to consider that patients will be active, empowered consumers of the solution. It’s no longer enough simply to get a solution into prescribers’ hands — you need to create patient demand as well. Many things can help drive adoption of digital health innovations. The surge in telehealth and remote care, coupled with a move towards consumerisation and the fact that patients are increasingly taking ownership of their healthcare have all come together to create a high level of momentum. This can in turn create a flywheel effect where the more value that patients and prescribers perceive, the more likely it is for digital health solutions to achieve wide scale adoption. In other words, it’s a good time to be bringing new solutions to the market — if they can meet the criteria above.


DIGITAL HEALTH

SPONSORED BY

DIGITAL DERMATOLOGY: A GROWING ROLE FOR TECH IN SKIN DISEASE CARE

L

Jon Friis, founder and CEO of digital skin health platform Miiskin, explains the acceleration that has been seen in technology used in dermatology.

ike many areas of healthcare, the challenges of the past two years have accelerated tech innovation within dermatology – leading to increasing digital collaboration with patients and research into new models of care for skin disease. Dermatologists rapidly adapted their approach to support patients during the pandemic, and technology that was adopted out of necessity, is now leaving a lasting mark on the future of dermatology. Research by the American Academy of Dermatology showed a surge in use of teledermatology - with 96.9% of dermatologists using it, compared to just 14.1% pre-COVID, according to its survey of members in 2020. It was a trend set to continue, with 58% of dermatologists saying they would continue to use teledermatology after the pandemic too.

Two years on, and the transformation happening within dermatology is clear. Technology is being tailored to the remote collaboration needs of dermatologists - and in a specialism where close monitoring of visual aspects of a condition is so important, the digital role is advancing. THE RISE OF CONSUMER TECH From skin cancer to acne, skin-related diseases are prevalent. Two-in-three people have suffered from skin disease in their lifetime, according to the British Skin Foundation. In the UK alone, more than 100,000 new cases of skin cancer are reported each year, one-in-five children have eczema and there are a million people with psoriasis. Consumer tech has stepped up and we are using machine learning, computer vision and augmented reality to enhance the capabilities

of patients’ own tech. Most adults now come ready-equipped with the potential to instantly capture and share changes to their skin - and smartphone-friendly consumer versions of mole mapping, face tracking and full body imaging are making the process easier.

documentation of a skin condition. It can assist with prioritisation of care, drive efficiency within dermatology clinics, deliver patient engagement communication - and provide the bridge between consumer and clinical technology.

Tech is ready to play a more formal part in consultations and support research into new models of care. Couple this with the clinical demand for digital collaboration and the opportunity for innovation is on a growth trajectory.

A DIGITAL FOCUS IN SKIN RESEARCH During 2021, Miiskin PRO teledermatology went live in the US to facilitate the use of the consumer AI-powered skin tracking app with a secure platform for dermatologists to collaborate with their patients. Uptake with clinics has been fast and the asynchronous technology is now being adapted to support academic researchers too.

SCOPE FOR INNOVATION IN DERMATOLOGY There has been a huge mindset shift within clinical teams. Healthcare providers flocked to video consultations to allow continuation of care, with well-known live-videoconferencing services coming to the aid of many dermatologists during the pandemic. However, the opportunity for technology has gone beyond the realms of video call solutions in dermatology. A major digital growth area is asynchronous technology, which allows the exchange of high-definition patient photos and other structured patient-reported information by store-and-forward (SAF) communication. Asynchronous technology supports remote access to care and visual

With vital academic work happening around the world to stem the growth of skin disease, one of the current challenges for researchers is to find a digital health platform that can consistently gather and store their test subjects’ data in a secure and compliant way. We were first approached by an academic research team in the US for a specialist melanoma care research project – and have now opened our platform for wider academic use by dermatology researchers and their research participants. From an academic perspective, the platform can be used where skin tracking, and high quality selfcaptured skin images and structured information are required from patients taking part in research programmes. Digital interventions, such as health awareness messaging and clinical reminders, can also be delivered to patients via the app to support behaviour change.

27


Messe Frankfurt Group

15 – 18 NOVEMBER 2022 FRANKFURT / GERMANY

Enabling the impossible! We know that additive manufacturing offers undreamed-of potential. Only, however, if all the upstream and downstream processes are taken into account – from design to material and quality assurance. Does your technology contribute to AM? If so, do secure your space in Frankfurt. formnext.com

Where ideas take shape.


REGULATION

THE ETHICAL PARADOX: Regulation keeping pace with technology Fiona Maini, principal, global compliance and strategy at Medidata, a Dassault Systèmes company, writes about the regulatory issues surrounding artificial intelligence (AI) as its presence continues to grow in medtech and healthcare.

A

rtificial intelligence (AI) is a broad term, but it is often defined as a “software that can, for a given set of human-defined objectives, generate outputs such as content, predictions, recommendations, or decisions influencing the environments they interact with.” AI has wide applicability across the healthcare industry, from drug repurposing, imaging, and diagnostics to supporting healthcare providers with workflow management and using applications to assess a patient’s symptoms. The pandemic has shed additional light on the full potential of AI in helping the healthcare industry speed up the delivery of drugs. With the use of AI, researchers were, among other things, able to run algorithms to determine which drugs and treatments could be repurposed to treat patients with COVID-19. But relentless technological innovation in healthcare brings with it regulatory challenges. What can be done to address the risks around the use of AI? To what extent can AI be regulated to ensure it is used for the greater good? ETHICAL AI: CONSIDERATIONS While AI can be used for the greater good, it does pose some ethical challenges if not governed properly. The

healthcare industry is guided by a set of core ethical principles, set in place and recognised decades ago, including guidelines like the Declaration of Helsinki. The declaration has played a central role in setting ethical boundaries in healthcare to ensure the industry is keeping patients’ best interests at heart. It’s no surprise that with its rise in use and applicability, a similar approach has been adopted with AI. Researchers from Harvard Law School and the Massachusetts Institute of Technology Media Lab published a paper on adversarial attacks on medical machine learning, including techniques to corrupt otherwise-reliable systems. For example, it’s possible to manipulate AI diagnostics and alter pixels on a scan to indicate an illness or tumour that isn’t there, which clearly goes against the principles adopted by the wider industry. This needs to be monitored and properly legislated against. REGULATING AI TO ENSURE IT REMAINS ETHICAL To address ethical concerns raised by rapidly evolving technological advancements, regulators have launched several initiatives. For instance, the European Union Commission appointed members to a newly formed

AI High-Level Expert Group, with the purpose of providing advice on the Commission’s AI strategy. The group has delivered Ethics Guidelines for Trustworthy AI – which argues for a human centric approach to AI, and outlines guiding principles and seven core requirements AI systems need to meet to be considered trustworthy. These core requirements include the need for human agency and oversight, privacy and data governance and technical robustness and safety, amongst other things. Such ethical considerations also was a reference to the publication of a draft proposal by the EU Commission titled ‘The Artificial Intelligence Act’, the world’s first legal framework for the use of AI, which lays out a set of regulations to ensure the ethical use of AI within the EU. The proposal takes a four-tiered approach to the regulation of AI, with different rules being applied depending on the category in which a product or system falls. The tiers include AI systems that pose ‘minimal or no risk’, ‘limited risk’, ‘high risk’, and ‘unacceptable risk’. ‘Minimal or no risk’ includes AI systems like spam filters, while ‘unacceptable risk’ AI systems will be banned due to their threat to the safety, livelihood, and rights of people.

In parallel, the US Food and Drug Administration (FDA) released an action plan in 2021 on AI and machine learning, which outlines how regulatory oversight can help deliver safe and effective software functionality to improve the quality of care that patients receive. LEADING FROM THE FRONT: A UNITED INDUSTRY Regulators have taken a swift role in addressing ethical concerns raised by the use of AI in healthcare, through the review and implementation of guidelines and regulations. Whilst progress has been made, the problem persists that the pace at which technology is developing needs to be matched with the implementation of such regulations. Close collaboration and dialogue between all industry stakeholders and regulatory bodies is imperative to properly address this and mitigate the misuse of data. Fiona Maini will be participating in a panel session: Addressing the Challenges Presented by the Current Regulatory Device Environment, on Day One of Med-Tech Innovation Expo. For more information visit: www.med-techexpo.com

29


REGULATION

No room for error: Why technology holds the answer in labelling

Bob Tilling, VP global sales at Kallik, discusses how advanced technologies can ensure end-to-end consistency throughout the medical device labelling process, and ensure today’s pain points don’t extend into future operations.

I

n today’s medical device artwork and labelling operations, the focus rests on mitigating as many errors as possible. Relying on traditional, manual methods won’t suffice in an increasingly complicated landscape – and it’s time organisations looked to new approaches for the future to reduce risks and avoid costly mistakes. The antidote lies with technology, where the automation of tasks, such as thorough quality checks and the population of preapproved key phrases and symbols into a single source of truth is essential. The payback in business terms is huge. In turn, these will significantly improve the processing times for thousands of products, identify mistakes before they go to market and form a master source of approved data, equipped to support medical device manufacturers in a smooth labelling process. COMMUNICATION IS KEY – IN EVERY LANGUAGE With new medical devices being trialled every day across the globe, demand for both creation and management of artwork and labelling is extremely high. Of course, major regulatory changes are also common in other

30

industries. Kallik has seen a sharp rise in the number of major brands looking for help – one leading multinational consumer goods company currently has over 300,000 current pieces of artwork, which require up to 60,000 minor changes per year. With this sheer volume of assets, even 1% of these with an error could be a highly expensive and time-consuming task to rectify. For pharma and medical device organisations where regulation and compliance issues are top of the agenda, companies must ensure communication across the whole supply chain – from production and storage to transport and distribution. Information must be clear, easy to read and localised in its respective language. The translation process poses a significant risk to label printing, as the upkeep of just one

sentence across numerous languages is an arduous task. An end-to-end labelling and artwork management solution such as Veraciti takes approved translated data and automatically triple-checks the information before printing. COMPLIANCE PRESSURES SQUEEZE MEDICAL DEVICE ORGANISATIONS FROM MULTIPLE ANGLES Regulatory changes affecting labelling and artwork are frequent. Previous EU MDR requirements saw Class II medical device organisations overhaul their existing labels, and upcoming IVDR regulatory deadlines and UKCA certification by January 2023 will see countless medical device businesses alter their labels yet again to stay compliant. While the rules are clear, the job at hand will not be an overnight fix, and organisations will need to ensure their data is in order – in advance – to succeed. The effects will be felt globally, as alongside UK businesses, those exporting to the UK will also need to ensure they are UKCA-complaint.


REGULATION

The global pandemic had its own role to play in accelerating these pressures. When most employees worked remotely and on alternative hours, communication became a challenge. With this disconnect hindering approval times, processes, and accuracy particularly in the first year, attention pivoted to speeding operations up efficiently and safely, using software to centralise data. REDUCING ARTWORK APPROVAL TIME BY 70% Manual quality checks, inperson reviews and laborious approval processes – moving artwork through these stages has historically taken numerous weeks. The answer lies in a collaborative approach, one that provides enhanced visibility and can significantly reduce artwork approval times from an average of around 18 weeks, down to as little as five. This works in conjunction with automation – ensuring one master design label has all the populated information, to allow other future labels to use this as a foundation. All edits and contributions can also be viewed by each stakeholder, and artwork can be reviewed the same day with the ability to add visible comments or annotations for clear communication. By using a comparison tool, any differences between two versions of a label are highlighted to ensure approvers are only reviewing the newest and latest edits, to avoid wasting valuable time analysing the entire artwork.

Previous EU MDR requirements saw class II medical device organisations overhaul their existing labels and IVDR regulatory deadlines and UKCA certification by January 2023 will see countless medical device businesses alter their labels yet again to stay compliant HOW ONE ERROR CAN AFFECT THE WHOLE SUPPLY CHAIN… OR WORSE Errors can be made at various stages but only around half are captured internally. Frequently, these mistakes are discovered between warehouses or in the design stages, where they must be recorded. It is software that focuses on preventative measures to these error challenges, with methods to capture errors before they cause any damage, such as professionally approved and stored data and rigorous quality control processes. It's against a consumer-facing backdrop that we see the need for accurate labelling and a single source of truth to be so critical. With information on how to use, store and maintain medical devices all critical to the health and safety of patients, an error in printing could have severely harmful consequences. For example – ‘1-2’ tablets becoming ‘12’ subsequently presents a major risk to life.

finding an artwork and label management solution that will suit the changing needs of their business – no matter the industry. From the building and configuration to the migration of large data, end-to-end solutions can reduce a year of integration down to three months to reduce disruption and save organisations substantial costs. Once all the content needed to create a new version of a label is decided, the information can be automatically populated into the correct fields using a set of pre-configured rules, to drive regulatory compliance across labelling and artwork management activities. There really is no room for errors in medical device labelling. With the largest number of product errors occurring at the artwork and labelling stage, embracing a digital solution capable of preventing these mistakes before they become a significant issue is vital.

AVOID POTENTIAL FUTURE MISHAPS As the market evolves, companies have increased their focus on

31


Asset/Library Management Software Complete equipment lifecycle management RFID & barcode tracking Integration with other software Fully customisable interface, processes and reports

IndySoft Europe Linford Forum, Milton Keynes, Buckinghamshire MK14 6LY United Kingdom

+44 (0)1908 904 116 sales@indysoft.co.uk www.indysoft.com

VHS valves and nozzles advert_Layout 1 22/08/2017 10:54 Page 1

Solenoid Valves and Nozzles for Microdispensing ● High Speed Operation, up to 1200 Hz ● Operating pressures up to 120 psi ● Wide range of seal materials ● 12 or 24 vdc The Lee VHS valves are designed for high speed, precision micro-dispensing of fluids. When combined with a matching nozzle, they are suitable for applications requiring microliter and nanolitre dispense volumes. The valves are available with outlet ports for push on tubing, 062 Minstac fittings or with an integral jewelled orifice in three different diameters and are designed for a life of 250 million cycles.

For more information visit www.leeproducts.co.uk Tel: 01753 886664

Fax: 01753 889588

email: sales@leeproducts.co.uk

Lee Products Limited, 3 High Street, Chalfont St Peter, Gerrards Cross, Bucks. SL9 9QE

Innovation in Miniature


Meet the start-up

SPONSORED BY

MEET THE START P:

SENSING SMARTER CARE Jim Patience, CEO of Anthropos tells Med-Tech Innovation about its technology platform that’s aiming to change the face of care in the UK.

First, tell us about Anthropos? Anthropos is a technology platform, aiming to change the face of care in the UK. The platform connects to discreet, smart sensors around the home – which provide data we turn into usable intelligence that carers and family members can use to spot changes in the daily routines of an older person. This might include insight into how active an older person is, if they are managing their food and drink intake or if they are experiencing issues sleeping at night. In 2022, we are continuing to evolve the platform to address other key, preventable health concerns for older people.

like kettles, which could indicate if an older person is drinking too little or is repetitively boiling the kettle. The sensors monitor 24/7 and connect to the Anthropos platform, which turns the raw data into intelligence, offering insights into the older person’s routine and flagging any big changes or areas of concern. For example, if an older person is going to the toilet more often, this could indicate a UTI, which if left untreated, could become serious. Carers and family members can then use these insights to take immediate action, or to tweak their loved one’s care plan and ensure they’re getting the support they need.

Connected health has exploded since the pandemic, how’s your approach to it different? The mission at Anthropos goes beyond simply monitoring the daily lives of older people. Our goal is to ultimately prevent the preventable – spotting critical but subtle changes to the daily routine of an older person that indicate something could go wrong without intervention, such as seeing changes in the pattern of behaviour of an older person which could indicate they are at risk of a UTI. By focusing on pre-emptive care and prevention, we believe we can support older people to stay at home safe, well and independent for longer. Give us some insight into the platform that you’ve developed? The Anthropos platform connects to IoT devices and smart sensors that are placed around the home. These detect movement – so can be placed in bedrooms (to indicate night-time movement/waking), on fridges (to indicate lack of consumption), in bathrooms (to indicate frequency of toilet visits), among others. Smart plugs can also be connected to things

level of support her family and carers can offer her. Prior to the sensors being installed, Eileen had been continuously admitted to hospital with UTIs. But, within 48 hours of having the system in place, the sensors identified that Eileen wasn’t drinking any liquids after her carer left in the early morning – and so was developing UTIs because of her dehydration. Having this information meant Eileen’s carers and family could adapt her care plan accordingly, preventing further infections from occurring. Speaking about Anthropos, Eileen shared the heart-warming message: “The sensors are there, but I’m not aware of them all the time – just the secure feeling I am cared for and there’s always someone there for me.” Any plans to advance your offering? We already connect to over 50 devices and have been working to expand our product range to address more key health concerns for older people. We’re developing our solution to address three key preventables: falls, UTIs and medication mismanagement. These all tie into Anthropos’ mission: to prevent the preventable and keep older people at home safely for longer.

What results have you seen from the use of your platform so far? The platform has made a huge difference in the day-to-day lives of many older people. One key example of this is in our collaboration with Home Instead, and an 89-year-old woman named Eileen – a user of the Anthropos system. Eileen lives with Alzheimer’s and having the technology in her home has made a huge difference for the

Anything else you’d like to add? These are still early days for Connected Care Platforms like Anthropos, but you can expect to see us developing the platform to monitor the environment a person lives in, their patterns of behaviour, their wellbeing, and their safety and security. The development of this entire sector is being led by innovative start-ups who see an opportunity to change the models of both health and social care.


Tackling the “cocktail party problem” Ian Bolland caught up with Ori Goren, CEO and Tami Harel, director of clinical research and chief audiologist, from Nuance Hearing to discuss how its solutions aim to address the "cocktail party problem".

T

he cocktail party problem is when people find it hard to understand others in crowded spaces because background noise can override the sound of participants in a conversation. Nuance Hearing was founded by two well-known Israeli entrepreneurs – Zohar and Yehuda Zisapel. The company has now launched the Voice Selector Converse in the UK, a directional microphone to address the cocktail party problem which Goren believes has unmatched performance compared to other similar products on the market. The difference between Nuance’s technology and that of a hearing aid to address this issue, is the use of directional microphones. Tamil Harel explains: “One of the best ways to improve speech intelligibility in noise is to use directional microphones. So, we can know which direction the speech is coming from and which direction the noise is coming from and separate the two. “What the Voice Selector Converse offers is an array of eight microphones that are designed to capture sound for all directions to achieve a superior signal-to-noise ratio.” The company’s algorithms allow a specific focus on noise coming from one direction and limit the sound from elsewhere, while enabling the person operating the device to select where they wish to hear because of the eight microphones at their disposal – rather than with a device with two microphones which are operating quite closely together. The device can also operate automatically and follow the dominant speaker in conversation.

34

Goren explains that this device doesn’t mean that the users wouldn’t benefit or use hearing aids, but that the Voice Selector Converse is primarily for those who are trying to attain better hearing in crowded places, or do not need to always use a hearing aid; a situational device for a situational problem. He also said the device could pick up sound from up to five metres away. The device uses low latency neckband style earphones which, Goren admits, aren’t discrete, but as he says, the aim was to solve the problem above anything else. “Air pods and the like are great, but they are expensive, and people tend to lose them. Also, this is not a normal Bluetooth device, which would create a very annoying latency or delay between the reality and what you hear in your ears because it takes one tenth of a second until arrives. We have achieved a very high quality of audio using the neckband with a very sophisticated and very fast Bluetooth to allow a very low latency as well as comfort while using the device.

“Standard Bluetooth latency is over 120-130 milliseconds. But our tech only has a latency of 40 milliseconds. It was originally developed for gamers who need very low latency when they want to use wireless headphones. We are using this special protocol to achieve a good experience.” Accompanying the two pieces of hardware is an app that allows users to test their hearing and allow the user to control the device. Harel explains: “If I'm sitting at a table and I want to capture the voices of people sitting far away from me, I can move the device, using the app to manually change location of the speaker I want to listen to. It is a situational device, to help solve a situational problem to exert less effort in understanding speech in noisy environments.”


HEALTHY DATA MEANS HEALTHY WORKFLOWS AND HEALTHY PATIENTS.

InterSystems makes your data healthy so it’s accessible, useable, and ready for action.

HealthyData.com



Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.